文献速递临床免疫临床生化

suPAR对脓毒症的预后价值:急诊科患者管理的潜在工具

Prognostic value of suPAR in sepsis: a potential tool to support patient management in the Emergency Department.
PubMed 文献 · Clin Chem Lab Med · 2025-12-15

本研究回顾性分析急诊科收治的脓毒症或系统性感染患者,采用自动浊度免疫分析法检测入院时suPAR水平。主要终点为基线suPAR与死亡率的关系,次要终点为临床严重程度和预后预测。结果显示suPAR中位数6.99 μg/L,10.2 μg/L阈值与死亡率强相关,5.96 μg/L界值识别重症和住院延长患者。

要点

  • 急诊脓毒症患者入院suPAR中位数6.99 μg/L,与病情严重程度一致。
  • suPAR阈值10.2 μg/L与死亡率强相关,5.96 μg/L识别重症和住院延长。
  • 浊度免疫分析法可快速检测suPAR,辅助风险分层和分诊决策。

核心结论

  • suPAR似乎是急诊科脓毒症或系统性感染患者可靠、快速且有临床用的预后生物标志物。

研究设计与样本

  • 回顾性研究,在急诊科入院时对初步临床检查诊断为脓毒症或系统性感染的患者检测suPAR水平。
  • 使用自动浊度分析法(suPARnostic ViroGates试剂盒,Atellica CH分析仪,Siemens)检测suPAR。
  • 主要终点为基线suPAR水平与死亡率的关联,次要终点为临床严重程度指标和患者预后预测。

主要发现

  • 所有患者suPAR水平升高,中位数6.99 μg/L,与其临床病情严重程度一致。
  • suPAR阈值10.2 μg/L与死亡率强相关。
  • suPAR界值5.96 μg/L可识别重症疾病和住院时间延长的患者。

关键数值与推荐

  • suPAR中位数6.99 μg/L(所有患者)。
  • 死亡率相关阈值:10.2 μg/L。
  • 重症和住院延长识别界值:5.96 μg/L。

临床怎么用

  • 急诊科可通过自动浊度免疫分析法早期检测suPAR,辅助风险分层和分诊决策。
  • suPAR水平升高可提示脓毒症或系统性感染患者病情严重,需加强管理。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: The soluble urokinase plasminogen activator receptor (suPAR) is a well-established biomarker of immune activation, reflecting the severity of systemic inflammation. Recent evidence showed increasing interest in suPAR as a prognostic marker, with elevated levels consistently associated with greater disease severity and mortality, in different clinical settings. METHODS: In this retrospective study, suPAR levels were assayed at Emergency Department admission in patients who received a diagnosis of sepsis or systemic infection during their initial clinical workup, using an automated turbidimetric assay (suPARnostic ViroGates kit on Atellica CH analyzer Siemens). The primary endpoint of this study was to evaluate the association between baseline suPAR levels and mortality, while the secondary endpoint aimed to explore their potential as indicators of clinical severity and predictors of patient outcomes. RESULTS: suPAR levels were elevated in all patients (median 6.99 μg/L) consistent with the severity of their clinical condition. A threshold of 10.2 μg/L was strongly associated with mortality, while a cut-off of 5.96 μg/L identified patients with severe disease and prolonged hospital stays. CONCLUSIONS: suPAR seems to be a reliable, rapid, and clinically useful prognostic biomarker in the Emergency Department in patients with sepsis or systemic infections. Its early measurement by turbidimetric immunoassay in automation can support risk stratification, improve triage decisions, and enhance the management of these patients.

来源:Clin Chem Lab Med,查看原文。版权归原作者所有。

引用

  1. Leggeri S, Napoli G, Piccioni A, et al. Prognostic value of suPAR in sepsis: a potential tool to support patient management in the Emergency Department. Clin Chem Lab Med. 2025. PMID: 41380288. doi:10.1515/cclm-2025-1299

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。